StockData
Regeneron Pharmaceuticals, Inc. logo

Regeneron Pharmaceuticals, Inc. (REGN) stock

REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/307% above fair value
$951.19−8.22 (-0.86%)

Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –

Regeneron Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Regeneron Pharmaceuticals's total debt was $1.99B at Sep 30, 2026. For fiscal 2025 it was $1.99B, up 0.1% from the year before. The highest annual figure on record is $1.99B in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.99B+0.1%
FY2024Dec 31, 2024$1.98B+0.1%
FY2023Dec 31, 2023$1.98B+0.1%
FY2022Dec 31, 2022$1.98B+0.1%
FY2021Dec 31, 2021$1.98B+0.1%
FY2020Dec 31, 2020$1.98B–
FY2019Dec 31, 2019$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$1.99B+0.1%
Q2 FY2026Jun 30, 2026$1.99B+0.1%
Q1 FY2026Mar 31, 2026$1.99B+0.1%
Q4 FY2025Dec 31, 2025$1.99B+0.1%
Q3 FY2025Sep 30, 2025$1.99B+0.1%
Q2 FY2025Jun 30, 2025$1.99B+0.1%
Q1 FY2025Mar 31, 2025$1.98B+0.1%
Q4 FY2024Dec 31, 2024$1.98B+0.1%
Q3 FY2024Sep 30, 2024$1.98B+0.1%
Q2 FY2024Jun 30, 2024$1.98B+0.1%
Q1 FY2024Mar 31, 2024$1.98B+0.1%
Q4 FY2023Dec 31, 2023$1.98B+0.1%
Q3 FY2023Sep 30, 2023$1.98B+0.1%
Q2 FY2023Jun 30, 2023$1.98B+0.1%
Q1 FY2023Mar 31, 2023$1.98B+0.1%
Q4 FY2022Dec 31, 2022$1.98B+0.1%
Q3 FY2022Sep 30, 2022$1.98B+0.1%
Q2 FY2022Jun 30, 2022$1.98B+0.1%
Q1 FY2022Mar 31, 2022$1.98B+0.1%
Q4 FY2021Dec 31, 2021$1.98B+0.1%
Q3 FY2021Sep 30, 2021$1.98B+0.1%
Q2 FY2021Jun 30, 2021$1.98B+31.9%
Q1 FY2021Mar 31, 2021$1.98B–
Q4 FY2020Dec 31, 2020$1.98B–
Q3 FY2020Sep 30, 2020$1.98B–
Q2 FY2020Jun 30, 2020$1.50B–
Q4 FY2019Dec 31, 2019$0–

More Regeneron Pharmaceuticals figures

See a number that looks wrong?